Beta-adrenoreceptor blocking agents. Their role in reducing chances of recurrent infarction and death.
Survivors of myocardial infarction who have been discharged from the hospital face an increasing cumulative risk of suffering another infarction or death. beta-Adrenergic blocking agents have undergone various trials to reduce these risks and prolong life. Although earlier trials have shown conflicting results, recent studies have conclusively demonstrated the beneficial role of this class of drugs in reducing the chances of recurrent infarction and death. These studies are briefly reviewed and appropriate conclusions as well as recommendations are made.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D011433:Propranolol / Q000627:therapeutic use; D012008:Recurrence; D013565:Sympatholytics / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use
D013565:Sympatholytics; D013999:Timolol; D011433:Propranolol; D008790:Metoprolol